DUBLIN, May 10, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Cancer Immunotherapies Market 2016-2020" report to their offering.
The global cancer immunotherapies market is expected to grow at a CAGR of 15.17% during the period 2016-2020.
Cancer immunotherapy works by enhancing the innate powers of the immune system. This has better chances of successfully fighting cancer for a long period. Also, immunotherapies have fewer side effects and can treat different types of cancer. Cancer immunotherapies make up nearly 50% of the cancer drugs market.
The emergence of targeted and combination therapies are being developed to treat all types of cancer. Targeted therapies, which exploit the surface markers or properties of diseased or infected cells, cause fewer adverse effects than conventional non-targeted therapies. For example, in 20% of the cases, breast cancer is associated with the overexpression of HER2. In such circumstances, drugs such as Herceptin and Kadcyla, which target HER2 receptors, are administered as monotherapies or in combination. Targeting multiple pathways reduces the risk of developing treatment-resistant disorders. Thus, combination therapies, which target distinct mechanisms, are highly efficacious in treating cancer.
According to the report, an increased in the demand for cancer monoclonal antibodies will have a big impact on the market. The development and rising demand for cancer monoclonal antibodies have been attributed to the recent understanding of the type of cancer at the molecular level. Monoclonal antibodies have a high affinity for specific disease cells and areas that need treatment. The use of cancer monoclonal antibodies is growing, including therapies such as radioimmunotherapy and antibody-directed enzyme prodrug therapy (ADEPT). The rising use of these antibodies in drug development increases the revenue generation in the global cancer monoclonal antibodies market, thereby contributing to market growth.
Further, the report states that the expiry of drug patents will lead to reduced sales of key drugs.
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Takeda Pharmaceuticals
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Overview of cancer immunotherapies
PART 06: Pipeline portfolio
PART 07: Market landscape
PART 08: Market segmentation by type
PART 09: Geographical segmentation
PART 10: Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
For more information visit http://www.researchandmarkets.com/research/kmpc26/global_cancer
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets